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Abstract
Background: Depression is one of the most common reasons for consulting a General Practitioner (GP) within the
UK. Whilst antidepressants have been shown to be clinically effective, many patients and healthcare professionals
would like to access other forms of treatment as an alternative or adjunct to drug therapy for depression. A recent
systematic review presented some evidence that physical activity could offer one such option, although further
investigation is needed to test its effectiveness within the context of the National Health Service.
The aim of this paper is to describe the protocol for a randomised, controlled trial (RCT) designed to evaluate an
intervention developed to increase physical activity as a treatment for depression within primary care.
Methods/design: The TREAD study is a pragmatic, multi-centre, two-arm RCT which targets patients presenting
with a new episode of depression. Patients were approached if they were aged 18-69, had recently consulted their
GP for depression and, where appropriate, had been taking antidepressants for less than one month. Only those
patients with a confirmed diagnosis of a depressive episode as assessed by the Clinical Interview Schedule-Revised
(CIS-R), a Beck Depression Inventory (BDI) score of at least 14 and informed written consent were included in the
study. Eligible patients were individually randomised to one of two treatment groups; usual GP care or usual GP
care plus facilitated physical activity. The primary outcome of the trial is clinical symptoms of depression assessed
using the BDI four months after randomisation. A number of secondary outcomes are also measured at the 4-, 8-
and 12-month follow-up points including quality of life, attitude to and involvement in physical activity and
antidepressant use/adherence. Outcomes will be analysed on an intention-to-treat (ITT) basis and will use linear
and logistic regression models to compare treatments.
Discussion: The results of the trial will provide information about the effectiveness of physical activity as a
treatment for depression. Given the current prevalence of depression and its associated economic burden, it is
hoped that TREAD will provide a timely contribution to the evidence on treatment options for patients, clinicians
and policy-makers.
Trial registration: ISRCTN 16900744
Background
Depression is a leading contributor to disability in the
UK and is associated with a decrement of health greater
than many other chronic diseases [1,2]. It impacts not
only upon the life of the individual but also upon their
carers, employers and society as a whole [3-5]. Whilst
antidepressants are the most commonly prescribed
treatment for depression, there is concern about their
use and effectiveness, especially in mild/moderate cases
[6-8]. Cognitive behavioural therapy and counselling are
alternatives or adjuncts to medication, but access to
therapists within United Kingdom (UK) primary care is
variable and can involve long waiting times. For these
reasons, there is a need to identify other effective non-
pharmacological interventions for the management of
depression.
A recent systematic review presented some evidence
that physical activity could be an effective treatment for
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depression, although much of the research considered
had important limitations [9].
Many randomised controlled trials (RCTs) conducted
to date have recruited from a non-clinical setting or
have offered financial or other incentives to participate
[9,10]. Results from such trials are difficult to generalise
to patients who present routinely to primary care since
community volunteers or paid subjects are likely to dis-
play higher levels of motivation than potential partici-
pants who are identified within the clinical setting.
Reported trials have frequently been small and of poor
quality. Many have used inadequately concealed rando-
misation procedures or failed to conduct proper inten-
tion-to-treat (ITT) analyses, so may have exaggerated
any observed treatment effects [9,11]. Studies have also
generally been insufficiently powered to detect a mean-
ingful difference between the treatment groups, with
even the largest study reporting fewer than 50 partici-
pants per treatment arm [12].
Length of follow-up has been problematic, with those
studies of shortest duration often reporting the largest
effects, suggesting that any impact may be diminished
or disappear altogether in the longer term. Indeed, only
a small proportion of RCTs have investigated whether
any benefits outlasted the duration of the intervention
itself [13].
Little is known about the type, intensity or duration of
physical activity that might prove effective for the treat-
ment of depression. The context within which any inter-
vention is delivered may also be pivotal in terms of the
uptake and sustainability of physical activity for the indi-
vidual. Furthermore, any intervention will need to con-
sider the feasibility and practicality of delivery, as well as
addressing any issues of motivation, energy and self-
esteem prevalent within a depressed population.
Aim
The aim of this paper is to describe the protocol for an
RCT designed to evaluate an intervention developed to
increase physical activity, as a treatment for depression
within primary care.
Methods/design
Recruitment of participants and baseline assessment
The TREAD study is a pragmatic, multi-centre, two-arm
RCT into which patients recently diagnosed with a new
episode of depression are recruited from primary care
(as shown in Figure 1). Recruitment for the trial took
place over a 27-month period between August 2007 and
October 2009 in general practices from the Bristol and
Exeter areas. Patients could be included if they were
aged 18-69, had recently consulted their GP for depres-
sion and had either recently started taking antidepres-
sants (within four weeks of their baseline assessment
and following an antidepressant free period of at least
one month) or were not currently on antidepressants.
Ethical approval for the study was given by West Mid-
lands Multi-centre Research Ethics Committee (MREC)
and research governance approval was obtained from
the relevant local Primary Care Trusts (PCTs).
Individuals who were unable to complete self-adminis-
tered questionnaires in English, or had medical contra-
indications to physical activity, psychosis, bipolar
disorder or any serious substance abuse problem were
excluded from the study. Women pregnant at the time
of recruitment were also automatically excluded but
those women who became pregnant in the course of
their study participation were encouraged to continue
under their GP’s supervision.
The majority of patients referred to TREAD were
identified during routine consultations, when they were
given a patient information leaflet by their GP and, if
interested, asked to provide written authority to enable
further contact by the research team. In some practices,
computer systems were also regularly searched for
details of patients recently diagnosed as depressed or
prescribed an antidepressant, in an effort to alert GPs to
potentially eligible individuals. In this instance, patients
were sent information about the study from their sur-
gery and encouraged to respond to the research team
directly, if interested, using a reply-paid slip. Once a
referral was received, a researcher telephoned the
patient to introduce the study formally, make initial elig-
ibility checks and to arrange an appointment for base-
line assessment. Referred patients were visited at home
or at their GP surgery in order to obtain consent and
assess eligibility using the Clinical Interview Schedule
(CIS-R) [14] and the Beck Depression Inventory (BDI)
[15]. Only patients with a confirmed diagnosis of a
depressive episode according to the International Statis-
tical Classification of Diseases and Related Health Pro-
blems 10th Revision (ICD-10), a BDI score of at least 14
and informed written consent were included in the
study.
In addition to the RCT, a nested qualitative study will
investigate the experience and acceptability of the inter-
vention for both participants and health professionals.
An economic analysis will also be performed using a
quality of life measure and information gathered on
health service use to assess the cost effectiveness of the
intervention.
Randomisation procedure
Eligible and consenting patients were individually rando-
mised at the end of their baseline assessment to one of
two treatment groups; usual GP care or usual GP care
plus facilitated physical activity. Randomisation was stra-
tified to take account of antidepressant use (yes, no) and
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TREAD researcher contacts patient to arrange baseline assessment 
Practice computer systems screened for 
recent depression diagnosis.
Patient is sent a patient information sheet and 
reply slip to indicate interest in being contacted by 
TREAD research team
TREAD research team receive patient’s reply slip
Patient eligible
TREAD researcher telephones randomisation service to ascertain treatment allocation
GP refers patient to TREAD via fax
Patient randomised to ‘usual care’ groupPatient randomised to ‘intervention’ group
4-month follow-up (face-to-face)
(BDI score, SF-12 mental and physical health sub-scores, 
attitude towards physical activity, physical activity intensity and 
duration, self-reported antidepressant use) 
8-month follow-up (postal)
(BDI score, SF-12 mental and physical health sub-scores, 
attitude towards physical activity, physical activity intensity and 
duration, self-reported antidepressant use) 
12-month follow-up (face-to-face)
(BDI score, SF-12 mental and physical health sub-scores, 
attitude towards physical activity, physical activity intensity and 
duration, self-reported antidepressant use, antidepressant 
prescription over 12 months) 
Initial patient consultation with GP resulting 
in depression diagnosis
Patient is given patient information sheet and gives 
written consent for GP to make referral to TREAD 
research team
Figure 1 A flowchart of the TREAD trial design.
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minimised by severity of depression (CIS-R score of ≤25,
26-33, >34 at baseline), recruiting centre (Bristol, Exeter)
and level of physical activity (≤1, 2-3, >4 days per week
where at least 30 minutes of moderate intensity physical
activity was being undertaken). Allocation was concealed
from the researcher using an automated telephone ran-
domisation system which was administered remotely
and used a computer-generated code.
Follow-up
Follow-up data collection is scheduled at three time-
points; 4, 8 and 12 months post-randomisation. The 4-
month follow-up was chosen as the primary outcome
time point since it represents the stage in the interven-
tion period at which we expect to observe the largest
effect. The 8-month follow-up coincides with the end of
the intervention delivery, whilst the 12-month follow-up
will enable the investigation of any longer term effects of
the intervention on study outcomes. All follow-up data
collection employs a self-report research instrument.
In order to maximise retention, researchers meet
study participants to supervise the data collection pro-
cess at the 4 and 12-month follow-up points wherever
possible. Due to restricted resources, 8-month follow-up
is conducted solely using a postal questionnaire. Any
participants unable to attend their 4 and 12-month fol-
low-up sessions are contacted by telephone to arrange a
further appointment or sent the questionnaire by post if
re-arranging a face-to-face session is difficult.
Intervention
All study participants are encouraged to follow the
advice of their GP regarding depression and its treat-
ment throughout their involvement in the trial. In addi-
tion to this, participants in the intervention arm of the
study are offered the support of a Physical Activity
Facilitator (PAF) over an 8-month period. All PAFs are
trained specifically for the study and receive regular
supervision and feedback to maximise fidelity to model.
The TREAD intervention is theoretically-driven [16,17]
and tailored to address the specific challenges of isola-
tion, apathy and social anxiety which are common within
a depressed population. It aims to provide relatively
intensive, individually tailored support in a context that
will encourage maximum engagement in physical activity.
Following a specially developed manual, PAFs use a range
of motivational interviewing techniques and goal-setting
strategies to encourage participants’ uptake of a range of
acceptable and locally available physical activities. The
rationale and development of the TREAD intervention is
discussed in more detail in Haase et al [18].
The intervention comprises an initial hour-long, face-
to-face assessment session followed by a series of up to
ten short telephone contacts and two further half-hour,
face-to-face meetings, with the scheduling left to the
discretion of the PAF and the participant. The expecta-
tion is that at least five sessions including one face-to-
face meeting would be delivered by the primary
outcome point i.e. by 4-month follow-up.
Outcome measures
Primary outcome
The Beck Depression Inventory (BDI) [15] is collected
by self-report measure at the 4-month follow-up point
[15]. The resulting score is treated as both a continuous
(range 0 to 63) and binary (where less than 10 indicates
recovery) variable in order to provide a quantitative
measure of improvement and an estimate of the propor-
tion of patients reaching symptomatic recovery.
Secondary outcomes
The longer term effects of the intervention are mea-
sured using the BDI at the 8 and 12-month follow-up
points and the Short Form-12 Health Survey (SF-12)
[19] at 4, 8 and 12-month follow-up points. Attitude to,
and involvement in physical activity are also measured
by self-report at the same three follow-up points. Anti-
depressant use is assessed using a self-reported measure
of medication adherence at all three follow-up points
whilst GPs’ records will provide details of antidepressant
prescription over the entire 12-month follow-up period.
Statistical Analysis
The analysis and reporting of this trial will be undertaken
in accordance with Consolidated Standards of Reporting
Trials (CONSORT) guidelines [20] with the primary
comparative analyses conducted on an intention-to-treat
(ITT) basis using linear and logistic regression models
without imputation of missing outcome data. Descriptive
statistics of key clinical and socio-demographic variables
will be obtained as a means of detecting any marked
imbalance between the randomised groups at baseline,
with investigation of the effects on the primary analyses
of additional adjustment for any such variables.
The primary outcome measure (BDI score at 4-month
follow-up point) will be used and presented in both bin-
ary and a continuous form, adjusting for BDI score at
baseline and the stratification/minimisation variables.
For the continuous outcome, the result will be presented
as the (adjusted) difference in mean score between the
intervention and control groups. For the binary out-
come, the result will be presented as an (adjusted) odds
ratio of recovery in the intervention group compared
with the control group. Full attention will be paid to
95% confidence intervals as well as p-values.
The BDI score will also be considered in both binary
and continuous form in secondary analyses, using data
from the 4, 8 and 12-month follow-up points in a
repeated measures analyses. These will investigate
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whether any between-group differences alter over time,
and in the absence of any time effect, will yield an aver-
age effect over the three follow-up assessments. SF-12
sub-scores, attitude to physical activity, physical activity
level and self-reported antidepressant use will be ana-
lysed employing appropriate regression techniques at
4-month follow-up and also in a repeated measures ana-
lysis conducted using 4, 8 and 12-month follow-up data.
Antidepressant prescription data will be analysed as a
continuous variable using all data available in an appro-
priate regression model. Consideration will be given to
the adjustment of p-values for multiple testing.
The effect of missing data will be investigated by
generating a complete dataset using the Multiple
Imputation Chain Equation (MICE) method [21]. Com-
plier-Average Causal Effect (CACE) estimates [22], or
treatment efficiency, will be estimated using instrumental
variable regression and will compare outcomes for those
participants receiving an adequate ‘dose’ of the interven-
tion with a comparable group of would-be compliers in
the control arm. The extent and impact on the results of
clustering by general practice will also be investigated.
Sample size justification
The sample size calculation was based on the BDI score
as both a binary and a continuous outcome measure. As
it was initially thought that 10% of the population
would not be taking antidepressants at the time of
recruitment, the intention was to omit these individuals
from the primary analysis. The original calculation had
estimated that 60% of participants in the usual care
group and 73% in the intervention group would have
recovered by the 4-month follow-up, that is scoring <
10 on the BDI. A difference of 13% in the proportion
‘recovered’, equivalent to an odds ratio of 1.8, is consis-
tent with the lower end of treatment effects observed
with antidepressant medication and is considered clini-
cally worthwhile. With 90% power and 5% two-sided
alpha, 291 recruited patients would be required for each
treatment group. Previous studies using the BDI as a
continuous outcome have estimated a standard devia-
tion of about 9 points [23] and have suggested a worth-
while and feasible target difference of 3-4 points. Thus,
allowing for a maximum attrition rate of 15%, the
required sample size was initially calculated to be 762.
However, in the early stages of the trial, the percen-
tage of participants not on antidepressant treatment was
found to be almost 50%. Given the implications for total
sample size, and that allocation was stratified by antide-
pressant use, it was proposed that all randomised parti-
cipants should be included in the primary analysis. In
addition, whilst the recovery rate of the participants in
the control group was initially assumed to be around
60%, a recently concluded study [24] found that the pro-
portion of participants recovering in the equivalent
group was nearer to 20% (95% CI 12.9-30.3). Thus, the
original power calculations were revised to reflect a
reduced sample size of 360 patients randomised over a
27-month recruitment period.
As shown in Table 1, the revised power calculations
provide adequate power for the primary analysis using
the continuous outcome and, although there will inevi-
tably be some reduction in power for the binary out-
come, the ability to detect a 15% difference with 80%
power remains.
Discussion
This study has been designed to address the limitations
highlighted in previous research on the subject of physical
activity as a treatment for depression. All participants are
recruited directly from within the primary care setting,
thereby avoiding any undue influence from incentivisation
and allowing the results to inform clinical practice. The
study uses a remote randomisation system to protect con-
cealment of allocation and proposes that the primary com-
parative analyses be conducted on an ITT basis in
accordance with the CONSORT guidelines [20].
A two-arm design, with 180 participants per group
should provide sufficient power to detect a meaningful
difference in outcome. There will also be important sup-
plementary CACE analyses to estimate efficiency in the
presence of non-compliance with the intervention. All
participants will be followed-up for a 12-month period,
in order to consider the impact of the intervention in
both the immediate and longer term. Finally, the inter-
vention has been specifically developed to extend the
scope of existing successful interventions and has robust
theoretical underpinnings.
Physical activity, if found to be effective, could be an
important alternative or adjunct treatment for depression,
Table 1 Sample Size Calculation
total N
randomised
N for primary
analysis
power for 60% vs. 73%
(OR = 1.80) 1
power for 20% vs. 33%
(OR = 1.97) 2
detectable difference with
80% power 3
power to detect 3 BDI
point difference
360 306 63% 69% 15% 82%
1 based on original sample size.
2 revised calculation based on data from the IPCRESS study [24].
3 percentage difference of intervention group from usual care group assuming 20% recovery in usual care group.
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particularly for those who prefer non-pharmacological
interventions. Currently, however, little is known about
the mechanisms that might mediate any therapeutic
effects of physical activity on depression. There are a num-
ber of hypothesised biological and psychosocial mechan-
isms but it is likely that an effective physical activity
intervention would rely on multiple mechanisms. TREAD
aims to evaluate, in general terms, whether physical activ-
ity can be an effective treatment for depression within pri-
mary care. Future research might identify which particular
mechanisms, and any interactions between them, are most
effective, as well as determining the optimum type, inten-
sity and duration of physical activity required to produce a
therapeutic effect.
Current Study Status
The TREAD trial began recruiting patients in August
2007 and closed to recruitment in October 2009. Data
collection is due to be completed in November 2010
and results will be published in February 2011.
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